(ELTP)

Role: EVP Operations
Signature: /s/ Doug Plassche
Issuer symbol: ELTP
Transactions as of: 22 Aug 2025
Net transactions value: -$187,150
Form type: 4
Filing time: 26 Aug 2025, 17:17:39 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
ELITE PHARMACEUTICALS INC /NV/	EVP Operations	165 LUDLOW AVENUE, NORTHVALE,	/s/ Doug Plassche	26 Aug 2025	0001053369

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELTP	Common Stock	Sale	$262,150	-500,000	-22%	$0.5243	1,800,000	22 Aug 2025	Direct	F1
transaction	ELTP	Common Stock	Options Exercise	$75,000	+2,500,000	+139%	$0.0300	4,300,000	25 Aug 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTP	Stock Options (right to buy)	Options Exercise	$0	-2,500,000	-50%	$0.000000	2,500,000	25 Aug 2025	Common Stock	2,500,000	$0.0300	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4
F2	All of the stock options were fully vested and exercisable as of the transaction date.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.56, inclusive. The reporting person undertakes to provide to Elite Phannaceuticals, any security holder of Elite Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(1) to this Form 4

All of the stock options were fully vested and exercisable as of the transaction date.